חובות לטווח קצר של החברה: simulations-plus.com (SLP)

Simulations Plus, Inc. (SLP) generates revenue by providing clinical trial simulation software to global pharma behemoths and the FDA. The business relies on demand from scientists seeking to reduce costs and accelerate drug launches. The biosimulator developer maintains a healthy balance by increasing sales and acquiring niche IT startups. The indicator stands at 0.00. This chart illustrates the market's valuation dynamics of the asset relative to short-term liabilities.

Comparing short-term liabilities with current assets allows an investor to assess the risk of cash flow gaps. This metric aggregates all payments with a maturity of up to twelve months, measuring the issuer's operational solvency. The high margins of the Simulations Plus (SLP) software business and management's expertise ensure an exceptionally clean balance sheet. The absence of borrowings confirms the financial stability of the model. The stability of these credit obligations under one year indicates a lack of debt burden.